BREVETOXIN PBTX-3

Product NameBREVETOXIN PBTX-3
CAS85079-48-7
MFC50H72O14
MW897.1
EINECS
MOL File85079-48-7.mol

Chemical Properties

Density	1.190±0.06 g/cm3(Predicted)
storage temp.	-20C
solubility	DMSO: soluble,Ethanol: soluble,Methanol: soluble
form	Solid
pka	13.78±0.70(Predicted)
color	White to off-white
InChIKey	BKMHDYJRAAJTAD-FGRVLNGBSA-N

Safety Information

RIDADR	3172
WGK Germany	WGK 2
RTECS	XW5885000
HazardClass	6.1(a)
PackingGroup	I
Storage Class	3 - Flammable liquids
Hazard Classifications	Acute Tox. 4 Dermal Acute Tox. 4 Inhalation Acute Tox. 4 Oral Eye Irrit. 2 Flam. Liq. 2

Usage And Synthesis

Uses

Brevetoxin-3 (PbTx-3) is a potent allosteric voltage-gated Na+channel activator and has multiple active centers (A-ring lactone, C-42 of R side chain)[1]. Brevetoxin-3 (PbTx-3) has a high affinity to site 5 of the voltage-sensitive Na+channels, inhibits the inactivation of Na+ channels and prolongs the mean open time of these channels. Brevetoxin-3 (PbTx-3) repeated exposures can lead to prolonged airway hyperresponsiveness (AHR) and lung inflammation[2].

General Description

Lipid-soluble polyether marine toxin produced by the red tide dinoflagellate, Ptychodiscus brevis, found along the Gulf Coast of Florida. Voltage-dependent Na⁺ channel activator that causes contractile paralysis in animal models by binding to a unique site on these channels. The excitatory action of brevetoxins on nerve and muscle membranes is responsible for a wide spectrum of the toxic effects, including massive transmitter release from nerve endings, muscle fasciculations, and ventricular fibrillation. The toxin does not bind to either tetrodotoxin or aconitine/veratridine sites.

Biochem/physiol Actions

Primary TargetVoltage-dependent Na+ channel activator

Safety Profile

A poison by ingestion, intraperitoneal, and intravenous routes. When heated to decomposition it emits acrid smoke and irritating vapors.

in vivo

Brevetoxin-3 (PbTx-3)(intratracheal instillation; 2.8 μg/kg; gestational days 15-18)radioactivity is detected in placentas and fetuses within 0.5 hours. Concentrations of brevetoxin equivalents in fetuses are approximately 0.3 ng/g throughout the 48-h post-dosing, resulting in a calculated dose to fetuses of 19 ng/gh. Following brevetoxin infusion, concentration of brevetoxin equivalents in fetuses is 0.1 ng/g, lower than that present in most maternal tissues^[3]. .

Animal Model:	Pregnant CD-1 mice^[3]
Dosage:	2.8 μg/kg
Administration:	Intratracheal instillation; 2.8 μg/kg; gestational days 15–18
Result:	Demonstrated placental transport of brevetoxin or its metabolites following maternal acute exposure.

References

[1] Jeglitsch G,et al. Brevetoxin-3 (PbTx-3) and its derivatives modulate single tetrodotoxin-sensitive sodium channels in rat sensory neurons.J Pharmacol Exp Ther. 1998 Feb;284(2):516-25. PMID:9454792
[2] Zaias J,et al. Repeated exposure to aerosolized brevetoxin-3 induces prolonged airway hyperresponsiveness and lung inflammation in sheep.Inhal Toxicol. 2011 Mar;23(4):205-11. DOI:10.3109/08958378.2011.558936
[3] Benson JM, et al. Placental transport of brevetoxin-3 in CD-1 mice.Toxicon.2006 Dec 15;48(8):1018-26. Epub 2006 Aug 18. DOI:10.1016/j.toxicon.2006.08.008

BREVETOXIN PBTX-3

Chemical Properties

Safety Information

Usage And Synthesis

Preparation Products And Raw materials

BREVETOXIN PBTX-3 Supplier

BREVETOXIN PBTX-3 manufacturers

Related Product Information